In the ARRECTOR phase 3 trial, roflumilast foam (0.3%) significantly improved psoriasis symptoms on the scalp and body, outperforming a vehicle control in both efficacy and safety.

66.4% of roflumilast-treated patients achieved clear or almost clear scalp psoriasis (S-IGA success) vs. 27.8% with the vehicle. Body-IGA success rates were 45.5% vs. 20.1%, and more patients reached PASI-75 and PSSI-75 (50.1% vs. 16.8%). The treatment was well-tolerated, with minimal adverse events.

These findings position roflumilast foam as a promising monotherapy for managing psoriasis.

Source: JAMA Dermatology | [Read Full Story](https://jamanetwork.com/journals/jamadermatology/fullarticle/2833460